TG Therapeutics
TGTX
132 hedge funds and large institutions have $534M invested in TG Therapeutics in 2018 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 50 increasing their positions, 36 reducing their positions, and 16 closing their positions.
141% more call options, than puts
Call options by funds: $20.8M | Put options by funds: $8.63M
44% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 16
39% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 36
6% more funds holding
Funds holding: 125 → 132 (+7)
1.11% more ownership
Funds ownership: 51.07% → 52.17% (+1.1%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3% less capital invested
Capital invested by funds: $548M → $534M (-$13.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$24.8M |
| 2 |
Wells Fargo
San Francisco,
California
|
+$11.7M |
| 3 |
BlackRock
New York
|
+$8.33M |
| 4 |
State Street
Boston,
Massachusetts
|
+$8.17M |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$4.82M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$16M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$8.57M |
| 3 |
SAM
Senzar Asset Management
New York
|
-$6.11M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
-$3.85M |
| 5 |
UBS AM
Chicago,
Illinois
|
-$3.5M |
TGTX Hedge Fund Activity: Q2 2018 in Review
132 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in TG Therapeutics (TGTX) for Q2 2018, worth a combined $534M — down 2.5% from $548M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new TGTX positions and 16 closed out — a net gain of 7 holders — while 50 added to existing stakes and 36 trimmed.
The largest buyer was RA Capital Management, adding an estimated $24.8M. The largest seller was Fidelity Investments, cutting an estimated $16M.
- 132 institutional investors held TG Therapeutics (TGTX) as of Q2 2018, up from 125 in Q1 2018.
- Funds reported $534M of TG Therapeutics stock for Q2 2018, down 2.5% quarter-over-quarter.
- 23 funds opened new TG Therapeutics positions in Q2 2018 and 16 closed out, a net change of +7 holders.
- The largest TG Therapeutics buyer in Q2 2018 was RA Capital Management, an estimated $24.8M added.
- The largest TG Therapeutics seller in Q2 2018 was Fidelity Investments, an estimated $16M sold.
Based on aggregated 13F filings for Q2 2018.